Innovative cancer immunotherapy, anti-PD-1 antibody Nivolumab

被引：0
|
作者：
Shibayama, Shiro [1 ]
机构：
[1] ONO Pharm, Res Cent Immunol, Osaka, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2017年 / 133卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
1-CS-01-1
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [41] The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
    Feng, Yingcai
    Hong, Yuan
    Sun, Hanzi
    Zhang, Bo
    Wu, Hongfu
    Li, Kang
    Liu, Xuesong
    Liu, Ye
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [42] Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy
    McLeod, Howard L.
    Mariam, Arshiya
    Schveder, Kimberly A.
    Rotroff, Daniel M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 103 - +
  • [43] Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report
    Narumi, Yoshitsugu
    Yoshida, Ryohei
    Minami, Yoshinori
    Yamamoto, Yasushi
    Takeguchi, Shiori
    Kano, Kohei
    Takahashi, Kae
    Saito, Tsukasa
    Sawada, Jun
    Terui, Hiroya
    Katayama, Takayuki
    Sasaki, Takaaki
    Ohsaki, Yoshinobu
    [J]. BMC CANCER, 2018, 18
  • [44] Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report
    Yoshitsugu Narumi
    Ryohei Yoshida
    Yoshinori Minami
    Yasushi Yamamoto
    Shiori Takeguchi
    Kohei Kano
    Kae Takahashi
    Tsukasa Saito
    Jun Sawada
    Hiroya Terui
    Takayuki Katayama
    Takaaki Sasaki
    Yoshinobu Ohsaki
    [J]. BMC Cancer, 18
  • [45] Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma
    Nakamura, Kenta
    Ashida, Atsuko
    Kiniwa, Yukiko
    Okuyama, Ryuhei
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (09) : 887 - 895
  • [46] Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma
    Kenta Nakamura
    Atsuko Ashida
    Yukiko Kiniwa
    Ryuhei Okuyama
    [J]. Archives of Dermatological Research, 2022, 314 : 887 - 895
  • [47] Precipitation of type 1 diabetes with anti-PD-1 immunotherapy
    Hussein, Ahmed
    Duke, Anna
    McLean, Mark
    Hng, Tien-Ming
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 89 : 90 - 90
  • [48] Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
    Su, Xin
    Li, Jian
    Xu, Xiao
    Ye, Youbao
    Wang, Cailiu
    Pang, Guanglong
    Liu, Wenxiu
    Liu, Ang
    Zhao, Changchun
    Hao, Xiangyong
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [49] Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
    Issafras, Hassan
    Fan, Shilong
    Tseng, Chi-Ling
    Cheng, Yunchih
    Lin, Peihua
    Xiao, Lisa
    Huang, Yun-Ju
    Tu, Chih-Hsiang
    Hsiao, Ya-Chin
    Li, Min
    Chen, Yen-Hsiao
    Ho, Chien-Hsin
    Li, Ou
    Wang, Yanling
    Chen, Sandra
    Ji, Zhenyu
    Zhang, Eric
    Mao, Yi-Ting
    Liu, Eugene
    Yang, Shumin
    Jiang, Weidong
    [J]. PLOS ONE, 2021, 16 (12):
  • [50] Durable complete response to immunotherapy with anti-PD-1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report
    Sekido, Katsuhisa
    Imaue, Shuichi
    Tomihara, Kei
    Tachinami, Hidetake
    Yamagishi, Kentaro
    Okazawa, Seisuke
    Ikeda, Atsushi
    Fujiwara, Kumiko
    Noguchi, Makoto
    [J]. CLINICAL CASE REPORTS, 2021, 9 (09):
12345